Study Identifies Subset of NSCLC Patients Who Experience Hyperprogression After Immunotherapy – Targeted Oncology
Targeted Oncology |
Study Identifies Subset of NSCLC Patients Who Experience Hyperprogression After Immunotherapy
Targeted Oncology A multicenter retrospective analysis presented at the 2017 ESMO Congress found that a newly defined subset of patients treated with anti-PD-1/PD-L1 immunotherapy experienced accelerated tumor growth indicative of hyperprogressive disease (HPD). |
